-
Published 9/29/2025
DeSanti E, Jankowich M, Choudhary G, Morrison A, Stanley ZK, Garshick E, Moy ML, Kang M, Wongtrakool C, Sadikot RT, Dempsey EC, Griffith M, Ha DM, Schmid CH, Goldstein RH, Rounds S. Study Design and Rationale for The Breathe Easier With Tadalafil Therapy for Exercise-Related Dyspnea in COPD-PH (BETTER COPD-PH). Pulm Circ. 2025 Oct; 15(4):e70167. PMID: 41036079.
-
Published 5/20/2024
Johnson SW, Wang RS, Winter MR, Gillmeyer KR, Zeder K, Klings ES, Goldstein RH, Wiener RS, Maron BA. Cluster analysis identifies novel real-world lung disease-pulmonary hypertension subphenotypes: implications for treatment response. ERJ Open Res. 2024 May; 10(3). PMID: 38770008.
-
Published 4/20/2024
Miller MS, Johnson SW, Opotowsky AR, Landzberg MJ, Sharma NS, Goldberg HJ, Wong AK, Witkin AS, Rodriguez-Lopez J, Goldstein RH, Maron BA, Wertheim BM. Iatrogenic esophageal dysmotility as a barrier to transplantation in pulmonary arterial hypertension. JHLT Open. 2024 Aug; 5:100098. PMID: 40143909.
-
Published 7/1/2022
Johnson SW, Finlay L, Mathai SC, Goldstein RH, Maron BA. Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing. Pulm Circ. 2022 Jul; 12(3):e12126. PMID: 36092795.
-
Published 3/14/2022
Maron BA, Choudhary G, Goldstein RL, Garshick E, Jankowich M, Tucker TJS, LaCerda KA, Hattler B, Dempsey EC, Sadikot RT, Shapiro S, Rounds SI, Goldstein RH. Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial. Pulm Circ. 2022 Jan; 12(1):e12043. PMID: 35506072.